This project aims to develop Cele-Pro, a first-in-class lymphatic-targeted oral prodrug of celecoxib, to restore gut lymphatic function for treating metabolic syndrome and pancreatic ductal adenocarcinoma (PDAC) By addressing abnormal lymphatic structure and function, the program targets broad chronic diseases, providing innovative therapies for conditions with unmet medical needs The project will establish a gut-lymphatic drug-delivery platform through IND-enabling studies, with the potential to treat multiple lymphatic-driven diseases by normalizing lymphatic function.